Pharmacy Question for the Week of December 13, 2021
Is the AMA’s definitive drug class listing catalog all-encompassing?
Is the AMA’s definitive drug class listing catalog all-encompassing?
Do we need to report the JW modifier in an OPPS hospital setting when a drug is discarded?
Regarding drug payment for those drugs acquired through the 340B Program, are there any updates to the ASP for 2022?
What is the correct way to report two drugs that are administered at the same time through two separate IV lines?
How do we charge for radiopharmaceuticals when introducing them in the lumbar canal as part of reporting 78630? Do you have any other tips for reporting this situation?
If a provider administers a therapeutic radiopharmaceutical under the hospital OPPS and plans to later perform a diagnostic scan, what should be done about the claim?
How is Iodine I-123 used for 78015?
What is the difference between white bagging and brown bagging regarding patient supplied drugs?
In terms of coding 78481, how should we go about reporting other non-radioactive drugs?
For definitive drug analysis, can you tell me more about the drug class listing?
If pre- and post-voiding images of the radiopharmaceutical are obtained and measurements are calculated to determine the
residual urine, how would this be reported?
Does the waste policy regarding the JW modifier apply to radiopharmaceuticals?
CPT® copyright 2024 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24